Hepatocellular carcinoma in patients with HCV

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 14, Issue 2, 2000, Pages 327-339

  Colombo, Massimo ^a  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma; Interferon; Liver transplantation; Screening

Indexed keywords

ACETIC ACID; ALCOHOL; ALPHA INTERFERON; HEPATITIS VACCINE;

ARTIFICIAL EMBOLISM; CANCER RISK; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; REVIEW; RISK FACTOR;

EID: 0034124475     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.1999.0079     Document Type: Article

References (105)

1. Ayoola E A, Odelola H A, Johnson A OK. Primary liver cancer (PLC) after non-A, non-B hepatitis (NANBH). Hepatology. 2:1982;154.
2. Resnick R H, Stone K, Antonioli D. Primary hepatocellular carcinoma following non-A, non-B post-transfusion hepatitis. Digestive Diseases and Sciences. 28:1983;908-911.
3. Kiyosawa K, Akahana Y, Nagata A, Furuta S. Hepatocellular carcinoma after non-A, non-B post-transfusion hepatitis. American Journal of Gastroenterology. 79:1984;777-781.
4. Gilliam J H, Geisinger K R, Richter J E. Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Annals of Internal Medicine. 101:1984;794-795.
5. Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 12:1990;671-675.
6. Kuo G, Choo Q L, Alter H J. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:1989;362-364.
7. Bosch F X, Munoz N. Hepatocellular carcinoma in the world: epidemiologic questions. Tabor E, Di Bisceglie A M, Purcell R H. Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America. 1991;35-54 Gulf Publishing Company, Houston.
8. Okuda K. Hepatitis C virus and hepatocellular carcinoma. Okuda K. Liver Cancer. 1997;39-49 Churchill Livingstone, New York.
9. El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine. 340:1999;745-750.
10. Bruix J, Barrera J M, Calvet X. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. ii:1989;1004-1006.
11. Colombo M, Kuo G, Choo Q L. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. ii:1989;1006-1008.
12. Chen D S, Kuo G C, Sung J L. Hepatitis C virus infection in an area hyperedemic for hepatitis B and chronic liver disease: the Taiwan experience. Journal of Infectious Diseases. 162:1991;817-822.
13. Dazza M C, Meneses L V, Girard P M. Hepatitis C antibody and hepatocellular carcinoma. Lancet. 335:1990;1216.
14. Hasan F, Jeffers L J, De Medina M. Hepatitis C-associated hepatocellular carcinoma. Hepatology. 12:1990;589-591.
15. Kaklamani E, Trichopoulos D, Tzonou A. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. Journal of the American Medical Association. 265:1991;1974-1976.
16. Kew M C, Houghton M, Choo Q L, Kuo G. Hepatitis C virus antibodies in Southern African blacks with hepatocellular carcinoma. Lancet. 335:1990;873-874.
17. Nishioka K, Watanabe J, Furuta S. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer. 67:1991;429-433.
18. Poynard T, Aubert A, Lazizi Y. Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology. 13:1991;896-901.
19. Saito I, Miyamura T, Ohbayashi A. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the USA. 87:1990;6547-6549.
20. Srivantanakul P, Parkin D M, Khlat M. Liver cancer in Thailand. II. A case control study of hepatocellular carcinoma. International Journal of Cancer. 48:1991;329-332.
21. Vargas V, Castells L, Esteban J I. High frequency of antibodies to hepatitis C virus among patients with hepatocellular carcinoma. Annals of Internal Medicine. 112:1990;232-233.
22. Yu M C, Tong M J, Coursaget P. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. Journal of the National Cancer Institute. 82:1990;1038-1041.
23. Ohkoshi S, Kato N, Kinoshita T. Detection of hepatitis C virus RNA in sera and liver tissues of non-A, non-B hepatitis patients using the polymerase chain reaction. Japanese Journal of Cancer Research. 81:1990;862-865.
24. Shibata M, Takeda S, Kudo T. Minus strand RNA of hepatitis C virus in liver tissues. Journal of Hepatology. 13:1991;379-380.
25. Tang L, Tanaka Y, Enomoto N. Detection of hepatitis C virus RNA in hepatocellular carcinoma by in situ hybridization. Cancer. 76:1995;2211-2216.
26. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. International Journal of Cancer. 75:1998;347-354.
27. Tradati F, Colombo M, Mannucci P M. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. Blood. 91:1998;1173-1177.
28. Tsukuma H, Hiyama T, Tanaka S. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. New England Journal of Medicine. 328:1993;1797-1801.
29. Takano S, Yokosuka O, Imazeki F. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 21:1995;650-655.
30. Shibata M, Morizane T, Uchida T. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet. 351:1998;1773-1777.
31. Ikeda K, Saitoh S, Suzuki Y. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. Journal of Hepatology. 28:1998;930-938.
32. Benvegnù L, Chemello L, Bernardinello E, Cavalletto L, Alberti A. Evidence for an association between etiology of cirrhosis and pattern of hepatocellular carcinoma (HCC) development. Italian Journal of Gastroenterology and Hepatology. 30:1998;A66.
33. Bruno S, Silini E, Crosignani A. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 25:1997;754-758.
34. Romeo R, Rumi M G, Del Ninno E, Colombo M. Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma. Hepatology. 26:1997;1077.
35. Tarao K, Ohkawa S, Shimizu A. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus positive cirrhotic patients. Cancer. 73:1994;1149-1154.
36. Borzio M, Treré D, Borzio F. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Journal of Clinical Pathology and Molecular Pathology. 51:1998;96-101.
37. Donato M F, Arosio E, Balestrieri M. Increased risk of hepatocellular carcinoma (HCC) in cirrhotic patients with high proliferating cellular nuclear antigen index (PCNA-I). Italian Journal of Gastroenterology. 30:1998;A66.
38. Colombo M, de Franchis R, Del Ninno E. Hepatocellular carcinoma in Italian patients with cirrhosis. New England Journal of Medicine. 325:1991;675-680.
39. Sato Y, Nakata K, Kato Y. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. New England Journal of Medicine. 328:1993;1802-1806.
40. Benvegnù L, Fattovich G, Noventa V. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Cancer. 74:1994;2442-2448.
41. Cacciola I, Pollicino T, Squadrito G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. New England Journal of Medicine. 341:1999;22-26.
42. Austin H. The role of tobacco use and alcohol consumption in the etiology of hepatocellular carcinoma. Tabor E, Di Bisceglie A M, Purcell R H. Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America. 1991;57-75 Portfolio, The Woodlands.
43. Yamauchi M, Nakahara M, Maezawa Y. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. American Journal of Gastroenterology. 88:1993;39-43.
44. Simmonds P, Alberti A, Alter H J. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 19:1994;1321-1324.
45. Rullier A, Le Bail B, Ghetti S. Immunohistochemical detection of HCV antigens in 23 hepatocellular carcinomas and surrounding cirrhotic tissue. Italian Journal of Gastroenterology and Hepatology. 30:1998;A66.
46. Ravaggi A, Natoli G, Primi D. Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells. Journal of Hepatology. 20:1994;833-836.
47. Shih C M, Lo S J, Miyamura T. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HUH-7 cells. Journal of Virology. 67:1993;5823-5832.
48. Lo S Y, Selby M J, Ou J H. Interaction between hepatitis C virus core protein and E1 envelope protein. Journal of Virology. 70:1998;5177-5182.
49. Ray R N, Lagging L M, Meyer K. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Research. 37:1996;209-220.
50. Ray R B, Lagging L M, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. Journal of Virology. 70:1990;4438-4443.
51. Hiramatsu H, Hayashi N, Katayama K. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 19:1994;1354-1359.
52. Ray R B, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology. 226:1996;178-182.
53. Ray R B, Steel R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. Journal of Biological Chemistry. 272:1997;10983-10986.
54. Moriya K, Fujie H, Shintani Y. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine. 4:1998;1065-1067.
55. Kawamura T, Furusaka A, Koziel M J. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology. 25:1997;1014-1021.
56. Pasquinelli C, Shoenberger J M, Chung J. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology. 25:1997;719-727.
57. Sakamuro D, Furukawa T, Takenagi T J. Hepatitis C virus non structural protein NS3 transforms NIH 3T3 cells. Journal of Virology. 69:1995;3893-3896.
58. Takenaka K, Adachi E, Nishizaki T. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology. 19:1994;889-894.
59. Fasani P, Sangiovanni A, De Fazio C. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis due to multiple etiological factors. Hepatology. 29:1999;1704-1707.
60. Ebara M, Ohto M, Kondo F. Strategy for early diagnosis of hepatocellular carcinoma (HCC). Annals of the Academy of Medicine of Singapore. 18:1989;83-89.
61. Gozzetto G, Belli L, Capussotti L. Liver resection for hepatocellular carcinoma in cirrhotic patients. Italian Journal of Gastroenterology. 24:1992;105-110.
62. Franco D, Capussotti L, Smadja C. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology. 98:1990;733-738.
63. Anthony P P. Primary carcinoma of the liver. A study of 282 cases in Ugandan Africans. Journal of Pathology. 110:1973;37-48.
64. Okazaki N, Yoshino M, Yoshida T. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer. 63:1989;2207-2210.
65. Ebara M, Ohto M, Shinagawa T. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 90:1986;289-298.
66. Barbara L, Benzi G, Gaiani S. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 16:1992;132-137.
67. Okuda H, Obata H, Motoike Y, Hisamitsu T. Clinicopathological features of hepatocellular carcinoma - comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology. 31:1984;64-68.
68. Shijo H, Okazaki M, Kogaemaru F. Influence of hepatitis B virus infection and age on mode of growth of hepatocellular carcinoma. Cancer. 67:1991;2626-2632.
69. Ikeda K, Saitoh S, Tsubota A. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer. 71:1993;19-25.
70. Llovet J M, Bustamante J, Castells A. Natural history of untreated non-surgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 29:1999;62-67.
71. Livraghi T, Bolondi L, Buscarini L. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Journal of Hepatology. 22:1995;522-526.
72. McMahon B J, London T. Workshop on screening for hepatocellular carcinoma. Journal of the National Cancer Institute. 83:1991;916-919.
73. Colombo M. Early diagnosis of hepatocellular carcinoma in Italy. A summary of a Consensus Development Conference held in Milan, 16 November 1990 by the Italian Association for the Study of the Liver (AISF). Journal of Hepatology. 14:1992;401-403.
74. Oka H, Kurioka N, Kim K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 12:1990;680-687.
75. Cottone M, Turri M, Caltagirone M. Screening for hepatocelluolar carcinoma in patients with Child's A cirrhosis: an 8 year prospective study by ultrasound and alphafetoprotein. Journal of Hepatology. 21:1994;1029-1034.
76. Toyoda H, Kumuda T, Nakano S. The significance of tumor vascularity as a predictor of long-term prognosis in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection. Journal of Hepatology. 26:1997;1055-1062.
77. Child C G III. The Liver and Portal Hypertension. 1964;Saunders, Philadelphia.
78. Iwatsuki S, Starzl T E, Sheahan D G. Hepatic resection versus transplantation for hepatocellular carcinoma. Annals of Surgery. 214:1991;221-229.
79. Mazzaferro V, Regalia E, Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine. 334:1996;693-699.
80. Nagasue N, Yukaya H. Liver resection for hepatocellular carcinoma: results from 150 consecutive patients. Cancer Chemotherapy Pharmacology. 23:1989;S78-S82.
81. Bruix J, Castells A, Bosch J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 111:1996;1018-1023.
82. Harada T, Shigemura T, Kodama S. Hepatic resection is not enough for hepatocellular carcinoma. A follow-up study of 92 patients. American Journal of Gastroenterology. 14:1992;245-250.
83. Bismuth H, Chiche L, Adam R. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Annals of Surgery. 218:1993;145-151.
84. Livraghi T, Goldberg S N, Lazzaroni S. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 210:1999;655-661.
85. Castellano L, Calandra M, Del Vecchio Blanco, de Sio I. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. Journal of Hepatology. 27:1997;862-870.
86. Pompili M, Rapaccini G L, de Luca F. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer. 79:1997;1501-1508.
87. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology. 27:1998;67-72.
88. Livraghi T, Giorgio T, Martin G. Hepatocellular carcinoma in cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 197:1995;101-108.
89. Muto Y, Moriwaki H, Ninomiya M. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. New England Journal of Medicine. 334:1996;1561-1567.
90. Pelletier G, Roche A, Ink O. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Journal of Hepatology. 11:1990;181-184.
91. New England Journal of Medicine. 332:1995;1256-1261.
92. Pelletier G, Ducreux M, Gay F. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Journal of Hepatology. 28:1998;129-134.
93. Matsui O, Kodoya M, Yoshikawa J. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 188:1993;79-83.
94. Lai C L, Wu P C, Chan G CB, Lok A SF, Lin H J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 62:1988;479-483.
95. Castells A, Bruix J, Bru C. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 109:1995;917-922.
96. Lancet. 352:1998;17-20.
97. Villa E, Camellini L, Dugani A. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Research. 55:1995;498-500.
98. Nishiguchi S, Kuroki T, Nakatani S. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.
99. Mazzella G, Accogli E, Sottili S. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. Journal of Hepatology. 24:1996;141-147.
100. Valla D C, Chevallier M, Marcellin P. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 29:1999;1870-1875.
101. Kasahara A, Hayashi N, Mochizuki K. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patient with chronic hepatitis C. Hepatology. 27:1998;1394-1402.
102. Ikeda K, Saitoh S, Arase Y. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1346 patients using statistical bias correction with proportional hazard analysis. Hepatology. 29:1999;1124-1130.
103. Lancet. 351:1998;1535-1539.
104. Fattovich G, Giustina G, Degos F. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. Journal of Hepatology. 27:1997;201-205.
105. Muto Y, Moriwaki H, Shiratori Y. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Digestion. 59:1998;89-91.